ANAHEIM, CA (UroToday.com) - Monday's sessions at the AUA Annual Meeting in Anaheim showcased several moderated posters. One standout presentation (which also won prizes) is summarized below.

Stenzl presented the abstract from Austria on the outcome of the first double blinded placebo controlled clinical trial on the results of tumor resection under white or 5-ALA induced fluorescence light. In contrast to previous studies, the current study did not find any benefit to blue light cystoscopic resection with regards to tumor recurrences, despite increased detection of tumors. They studied 381 patients from 7 Austrian and 2 German centers who were randomized between the two modalities of tumor resection/detection. While lesion based stratification showed 33% of CIS, 54% of dysplasia and 16% of pTa lesions were only seen with blue light, the 12 month recurrence free survival rate was 62% in these patients compared to 69% in the white light group (p=0.34), and these results were independent of individual risk groups. Since this represents real world multicenter data, it creates a reason to question the momentum behind enthusiasm for wide spread use of fluorescence cystoscopy in the community.

(ABST [1085])

Read a UroToday Highlight from another Award Winning Bladder Cancer Detection Presentation

UroToday.com Full Conference Reports

Written by Ashish M. Kamat, a Contributing Editor with UroToday.

Please log-in or register in order to submit comments.

Powered by AkoComment!